IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system

Journal of Pharmaceutical Sciences

Volumn 98, Issue 6, 2009, Pages 2001-2009

  Buch, Philipp ^a   Langguth, Peter ^a   Kataoka, Makoto ^b   Yamashita, Shinji ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b SETSUNAN UNIVERSITY   (Japan)

Author keywords

Biopharmaceutics classification system (BCS); Caco 2 cells; Dissolution; Food effect studies; In vitro in vivo correlations (IVIVC); Permeation

Indexed keywords

FENOFIBRATE; HEXAL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIET RESTRICTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG PENETRATION; DRUG SCREENING; DRUG SOLUBILITY; GASTROINTESTINAL TRACT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; POSTPRANDIAL STATE; SIMULATION; TABLET FORMULATION;

EID: 67049162366     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21576     Document Type: Article

References (45)

1. Ginski MJ, Taneja R, Polli JE. 1999. Prediction of dissolution-absorption relationships from a continuous dissolution/Caco-2 system. AAPS PharmSci 1:E3.
2. Kobayashi M, Sada N, Sugawara M, Iseki K, Miyazaki K. 2001. Development of a new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract. Int J Pharm 221:87-94. (Pubitemid 32524038)
3. Sugawara M, Kadomura S, He X, Takekuma Y, Kohri N, Miyazaki K. 2005. The use of an in vitro dissolution and absorption system to evaluate oral absorption of two weak bases in pH-independent controlled-release formulations. Eur J Pharm Sci 26:1-8. (Pubitemid 41097255)
4. Kataoka M, Masaoka Y, Yamazaki Y, Sakane T, Sezaki H, Yamashita S. 2003. In vitro system to evaluate oral absorption of poorly water-soluble drugs: Simultaneous analysis on dissolution and permeation of drugs. Pharm Res 20:1674-1680.
5. Motz SA, Klimundová J, Schaefer UF, Balbach S, Eichinger T, Solich P, Lehr CM. 2007. Automated measurement of permeation and dissolution of propranolol HCl tablets using sequential injection analysis. Anal Chim Acta 581:174-180. (Pubitemid 44781431)
6. Motz SA, Schaefer UF, Balbach S, Eichinger T, Lehr CM. 2007. Permeability assessment for solid oral drug formulations based on Caco-2 monolayer in combination with a flow through dissolution cell. Eur J Pharm Biopharm 66:286-295. (Pubitemid 46654772)
7. Charman WN, Porter CJH, Mithani S, Dressman JB. 1997. Physicochemical and physiological mechanisms for the effects of food on drug absorption: The role of lipids and pH. J Pharm Sci 86:269-282. (Pubitemid 27113759)
8. Custodio JM, Wu CY, Benet LZ. 2008. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev 60:717-733.
9. Fleisher D, Li C, Zhou Y, Pao LH, Karim A. 1999. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet 36:233-254. (Pubitemid 29178760)
10. Persson EM, Gustafsson AS, Carlsson AS, Nilsson RG, Knutson L, Forsell P, Hanisch G, Lennernas H, Abrahamsson B. 2005. The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. Pharm Res 22:2141-2151. (Pubitemid 41821594)
11. Welling PG. 1996. Effects of food on drug absorption. Annu Rev Nutr 16:383-415. (Pubitemid 26286859)
12. Dressman JB, Amidon GL, Reppas C, Shah VP. 1998. Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms. Pharm Res 15:11-22. (Pubitemid 28080861)
13. Dollery C. 1991. Therapeutic drugs, Vol.1. Edinburgh: Churchill Livingstone.
14. Kataoka M, Masaoka Y, Sakuma S, Yamashita S. 2006. Effect of food intake on the oral absorption of poorly water-soluble drugs: In vitro assessment of drug dissolution and permeation assay system. J Pharm Sci 95:2051-2061.
15. Patel N, Forbes B, Eskola S, Murray J. 2006. Use of simulated intestinal fluids with Caco-2 cells and rat ileum. Drug Dev Ind Pharm 32:151-161.
16. Yamashita S, Furubayashi T, Kataoka M, Sakane T, Sezaki H, Tokuda H. 2000. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur J Pharm Sci 10:195-204. (Pubitemid 30190095)
17. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. 1981. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4:879-885. (Pubitemid 12174128)
18. Heinzel G, Woloszczak R, Thomann P. TopFit: Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC, G. Fischer. 1993.
19. Holm P, Norling T. 2006. A tablet comprising a fibrate. WO 2006084475.
20. Cavallari C, Rodriguez L, Albertini B, Passerini N, Rosetti F, Fini A. 2005. Thermal and fractal analysis of diclofenac/Gelucire 50/13 microparticles obtained by ultrasound-assisted atomization. J Pharm Sci 94:1124-1134. (Pubitemid 40780778)
21. Passerini N, Perissutti B, Moneghini M, Voinovich D, Albertini B, Cavallari C, Rodriguez L. 2002. Characterization of carbamazepine-Gelucire 50/13 microparticles prepared by a spray-congealing process using ultrasounds. J Pharm Sci 91:699-707. (Pubitemid 34639633)
22. Rodriguez L, Passerini N, Cavallari C, Cini M, Sancin P, Fini A. 1999. Description and preliminary evaluation of a new ultrasonic atomizer for spray-congealing processes. Int J Pharm 183:133-143. (Pubitemid 29257959)
23. Hauss DJ. 2007. Oral lipid-based formulations. Adv Drug Deliv Rev 59:667-676. (Pubitemid 47285409)
24. Humberstone AJ, Charman WN. 1997. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev 25:103-128. (Pubitemid 27107794)
25. Jannin V, Musakhanian J, Marchaud D. 2008. Approaches for the development of solid and semi-solid lipid-based formulations. Adv Drug Deliv Rev 60:734-746. (Pubitemid 351215578)
26. Jaspart S, Piel G, Delattre L, Evrard B. 2005. Solid lipid microparticles: Formulation, preparation, characterisation, drug release and applications. Expert Opin Drug Deliv 2:75-87. (Pubitemid 40123884)
27. O'Driscoll CM, Griffin BT. 2008. Biopharmaceutical challenges associated with drugs with low aqueous solubility - The potential impact of lipid-based formulations. Adv Drug Deliv Rev 60:617-624.
28. Porter CJ, Pouton CW, Cuine JF, Charman WN. 2008. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev 60:673-691.
29. Pouton CW. 2006. Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 29:278-287. (Pubitemid 44740131)
30. Hanafy A, Spahn-Langguth H, Vergnault G, Grenier P, Tubic Grozdanis M, Lenhardt T, Langguth P. 2007. Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Deliv Rev 59:419-426. (Pubitemid 47260709)
31. Shepherd J. 1994. The fibrates in clinical practice: Focus on micronised fenofibrate. Atherosclerosis 110:55-63. (Pubitemid 24338985)
32. Peterson ML, Hickey MB, Zaworotko MJ, Almarsson Ö. 2006. Expanding the scope of crystal form evaluation in pharmaceu tical science. J Pharm Pharm Sci 9:317-326. (Pubitemid 46620646)
33. Dai WG, Pollock-Dove C, Dong LC, Li S. 2008. Advanced screening assays to rapidly identify solubility-enhancing formulations: High-throughput, miniaturization and automation. Adv Drug Deliv Rev 60:657-672.
34. Corsini A, Bellosta S, Davidson MH. 2005. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol 96:44-49. (Pubitemid 41598112)
35. Adam A, Schrimpl L, Schmidt PC. 2000. Some physicochemical properties of mefenamic acid. Drug Dev Ind Pharm 26:477-487. (Pubitemid 30225625)
36. Perrut M, Jung J, Leboeuf F. 2005. Enhancement of dissolution rate of poorly-soluble active ingredients by supercritical fluid processes Part I: Micronization of neat particles. Int J Pharm 288:3-10. (Pubitemid 39656449)
37. Rasenack N, Müller BW. 2002. Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm Res 19:1894-1900. (Pubitemid 36016039)
38. Swanepoel E, Liebenberg W, de Villiers MM, Dekker TG. 2000. Dissolution properties of piroxicam powders and capsules as a function of particle size and the agglomeration of powders. Drug Dev Ind Pharm 26:1067-1076. (Pubitemid 30736910)
39. Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin HC, Lennernas H, Zhong Y, Amidon GL, Yu LX. 2006. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 23:1675-1686. (Pubitemid 44200529)
40. Chiou WL, Barve A. 1998. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res 15:1792-1795. (Pubitemid 28524594)
41. DeSesso JM, Jacobson CF. 2001. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem Toxicol 39:209-228. (Pubitemid 32244129)
42. Fagerholm U. 2007. Prediction of human pharmacokinetics - Gastrointestinal absorption. J Pharm Pharmacol 59:905-916. (Pubitemid 47051070)
43. Merle L, Dangoumau J, Balabaud C. 1978. Effect of food and light schedule on bile flow in the rat. Cell Mol Life Sci 34:764-765. (Pubitemid 8345998)
44. Zhao YH, Abraham MH, Le J, Hersey A, Luscombe CN, Beck G, Sherborne B, Cooper I. 2003. Evaluation of rat intestinal absorption data and correlation with human intestinal absorption. Eur J Med Chem 38:233-243. (Pubitemid 36349666)
45. Zwart LL, Rompelberg CJM, Sips A, Welink J, Engelen JGM. 1999. Anatomical and physiological differences between various species used in studies on the pharmacokinetics and toxicology of xenobiotics. Rev Lit, RIVM report 623860010.